<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03065868</url>
  </required_header>
  <id_info>
    <org_study_id>KNUMC_15-1045</org_study_id>
    <nct_id>NCT03065868</nct_id>
  </id_info>
  <brief_title>Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp</brief_title>
  <official_title>Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp (Randomized Controlled Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyungpook National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the effect of H. pylori eradication on regression of H. pylori-related gastric
      polyp (Ranomized controlled trial)

        1. Study design: open labeled RCT

        2. Study group H. pylori eradication group (N=17), non-eradication group (N=15)

        3. Treatment plan

             1. Baseline EGD

                : 0.3-1cm sized polyp - bx &amp; CLO test (antrum &amp; body)

                ==&gt; if H. pylori positive and eligible patients, randomization

             2. Triple therapy

             3. UBT (4week after eradication)

             4. Follow-up EGD: gross finding, CLO test

        4. Evaluation of polyp regression

             1. disappear

             2. regression over 50% (size, number)

             3. no change or increase (size, number)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      (A) Study population

        1. inclusion HP-realetd polyp polyp size with 0.3cm-1cm 20 yr - 70yr

        2. exclusion peptic ulcer, healing stage or acute stage recent use of PPI within 4weeks
           Liver cirrhosis, renal insufficiency, other serious chronic or acute disease current
           infection of other bacteria, virus, or fungus cancer, psychologic disease heavy drinker
           drug abuser pregnant women, Penicillin allergy, digoxin, antifungal, wafarin previosu H.
           pylori eradication enroll gastric polyp with bleeding or malignant transformation tiny
           polyp less than 3mm.

      (B) Study method

        1. Study design: open labeled RCT

        2. Study group H. pylori eradication group (N=17), non-eradication group (N=15)

        3. Treatment plan

             1. Baseline EGD: 0.3-1cm sized polyp - bx &amp; CLO test (antrum &amp; body) ==&gt; if H. pylori
                positive and eligible patients, randomization

             2. Triple therapy

             3. UBT (4week after eradication) if eradication failure in triple therapy, 2nd line
                treatment (metroniazole based quadraple therpay) and the UBT (4week after
                eradication)

             4. Follow-up EGD (3-9M): gross finding, CLO test

        4. Evaluation of polyp regression

             1. disappear

             2. regression over 50% (size, number)

             3. no change or increase (size, number)

        5. Statistical analysis

             1. Chi-square test to compare polyp regression between treatment &amp; control group.

             2. t-test to compare continuous variables between treatment &amp; control group.

             3. Paired T-test to compare the size between baseline and follow-up EGD.

             4. Regression analysis: univariate &amp; multivariate analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 9, 2015</start_date>
  <completion_date type="Actual">April 30, 2019</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open labelled randomized controlled trial. randomization : 2015 September</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare regression rate of gastric polyps between H. pylori eradication and non-eradication groups. Regression of gastric polyp: one of below 1) Disappearance of gastric polyp 2) Reduction of polyp size over 50%</measure>
    <time_frame>up to 24months</time_frame>
    <description>Evaluation of the effect of H. pylori eradication on the regression of H. pylori associated gastric polyp
Study group
H. pylori eradication
H. pylori non-eradication
Definition of gastric polyp change:
Disappearance of gastric polyp
Reduction of polyp size over 50%
No change of size or increased size</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Gastric Polyp</condition>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>eradictaion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H. pylori eradication group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-eradication</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>H. pylori non-eradication group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)</intervention_name>
    <description>H. pylori eradication (Triple Therapy) as first line treatment if eradication failure, quadruple therpy will be provided as 2nd line treatment</description>
    <arm_group_label>eradictaion</arm_group_label>
    <other_name>Triple Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gastric polyp with current infection of H. pylori

          -  Gastric polyp size with 3mm-10mm

          -  Age of 20 yr - 70yr

        Exclusion Criteria:

          -  Gastric ulcer ir duodenal ulcer (healing stage or acute stage)

          -  Use of PPI within 4weeks

          -  Liver cirrhosis, renal insufficiency, other serious chronic or acute disease

          -  Current infection of other bacteria, virus, or fungus

          -  Any cancer, psychologic disease

          -  Heavy drinker

          -  Drug abuser

          -  Pregnant women

          -  Penicillin allergy

          -  Use of digoxin, antifungal, wafarin

          -  Previous H. pylori eradication

          -  Gastric polyp with bleeding or malignant transformation

          -  Tiny polyp less than 3mm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Su Youn Y Nam, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Su Youn Nam</name>
      <address>
        <city>Daegu</city>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 18, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyungpook National University Chilgok Hospital</investigator_affiliation>
    <investigator_full_name>Su Youn Nam</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <keyword>gastric polyp</keyword>
  <keyword>Helicobacter pylori eradication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

